Roche's investigational medicine entrectinib showed durable response of more than two year
Roche announced results for its investigational medicine entrectinib, from an integrated analysis of the pivotal phase II STARTRK-2, phase I STARTRK-1 and phase I ALKA trials, which showed entrectinib shrank tumours (ORR) in 77.4% of people with locally advanced or metastatic ROS1-positive NSCLC. September 24, 2018